BOSTON—Unless progress is made toward developing effective treatments for metabolic dysfunction-associated steatotic liver disease (MASLD), the prevalence of that chronic liver disease will continue to increase steadily, driving up the rates of cirrhosis, hepatocellular carcinoma, the demand for liver transplants and the number of liver disease-associated deaths, according to new research presented at The Liver Meeting 2023.
To estimate the disease burden of MASLD in U.S. adults over the